Oramed Pharmaceuticals Statistics
Total Valuation
ORMP has a market cap or net worth of $192.18 million. The enterprise value is $120.43 million.
| Market Cap | 192.18M |
| Enterprise Value | 120.43M |
Important Dates
The last earnings date was Monday, August 10, 2026, after market close.
| Earnings Date | Aug 10, 2026 |
| Ex-Dividend Date | Jan 16, 2026 |
Share Statistics
ORMP has 41.60 million shares outstanding. The number of shares has increased by 2.31% in one year.
| Current Share Class | 41.60M |
| Shares Outstanding | 41.60M |
| Shares Change (YoY) | +2.31% |
| Shares Change (QoQ) | +1.27% |
| Owned by Insiders (%) | 17.58% |
| Owned by Institutions (%) | 34.65% |
| Float | 31.77M |
Valuation Ratios
The trailing PE ratio is 1.13.
| PE Ratio | 1.13 |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.61 |
| P/TBV Ratio | 0.61 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.70 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.98, with a Debt / Equity ratio of 0.00.
| Current Ratio | 4.98 |
| Quick Ratio | 4.85 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 74.24% and return on invested capital (ROIC) is -5.23%.
| Return on Equity (ROE) | 74.24% |
| Return on Assets (ROA) | -3.42% |
| Return on Invested Capital (ROIC) | -5.23% |
| Return on Capital Employed (ROCE) | -4.05% |
| Weighted Average Cost of Capital (WACC) | 10.73% |
| Revenue Per Employee | n/a |
| Profits Per Employee | $43.52M |
| Employee Count | 4 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ORMP has paid $45.41 million in taxes.
| Income Tax | 45.41M |
| Effective Tax Rate | 20.62% |
Stock Price Statistics
The stock price has increased by +90.66% in the last 52 weeks. The beta is 1.19, so ORMP's price volatility has been higher than the market average.
| Beta (5Y) | 1.19 |
| 52-Week Price Change | +90.66% |
| 50-Day Moving Average | 4.47 |
| 200-Day Moving Average | 3.80 |
| Relative Strength Index (RSI) | 44.87 |
| Average Volume (20 Days) | 226,217 |
Short Selling Information
The latest short interest is 1.15 million, so 2.77% of the outstanding shares have been sold short.
| Short Interest | 1.15M |
| Short Previous Month | 1.03M |
| Short % of Shares Out | 2.77% |
| Short % of Float | 3.63% |
| Short Ratio (days to cover) | 5.08 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -14.52M |
| Pretax Income | 220.28M |
| Net Income | 174.06M |
| EBITDA | -14.40M |
| EBIT | -14.52M |
| Earnings Per Share (EPS) | $4.15 |
Balance Sheet
The company has $50.61 million in cash and $733,000 in debt, with a net cash position of $71.75 million or $1.72 per share.
| Cash & Cash Equivalents | 50.61M |
| Total Debt | 733,000 |
| Net Cash | 71.75M |
| Net Cash Per Share | $1.72 |
| Equity (Book Value) | 317.47M |
| Book Value Per Share | 7.68 |
| Working Capital | 42.68M |
Cash Flow
In the last 12 months, operating cash flow was -$5.21 million and capital expenditures -$9,000, giving a free cash flow of -$5.22 million.
| Operating Cash Flow | -5.21M |
| Capital Expenditures | -9,000 |
| Depreciation & Amortization | 122,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -5.22M |
| FCF Per Share | -$0.13 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of $0.25, which amounts to a dividend yield of 5.41%.
| Dividend Per Share | $0.25 |
| Dividend Yield | 5.41% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 6.03% |
| Buyback Yield | -2.31% |
| Shareholder Yield | 3.09% |
| Earnings Yield | 90.18% |
| FCF Yield | -2.70% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on January 23, 2013. It was a reverse split with a ratio of 1:12.
| Last Split Date | Jan 23, 2013 |
| Split Type | Reverse |
| Split Ratio | 1:12 |
Scores
ORMP has an Altman Z-Score of 1.39 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.39 |
| Piotroski F-Score | 1 |